Featured Research

from universities, journals, and other organizations

Exposure to worm infection in the womb may protect against eczema, study suggests

Date:
January 28, 2011
Source:
Wellcome Trust
Summary:
Exposure to worm infections in the womb may protect a newborn infant from developing eczema, a new study suggests. A large trial in Uganda showed that treating a pregnant woman for worm infections increased her child's chances of developing the allergic skin disease. This research supports the so-called 'hygiene hypothesis', which proposes that exposure to infections in early childhood can modify the immune system and protect the child from allergies later in life.

Exposure to worm infections in the womb may protect a newborn infant from developing eczema, a study funded by the Wellcome Trust suggests. A large trial in Uganda showed that treating a pregnant woman for worm infections increased her child's chances of developing the allergic skin disease.

Published this week in the journal Pediatric Allergy and Immunology, the research supports the so-called 'hygiene hypothesis', which proposes that exposure to infections in early childhood can modify the immune system and protect the child from allergies later in life.

The World Health Organisation estimates that one in five of the world's population suffers from allergic diseases such as asthma and eczema, but this epidemic is no longer restricted to developed countries: more than four out of five deaths due to asthma occur in low and lower-middle income countries. The declining incidence and prevalence of infectious diseases -- including chronic infection by worms known as helminths -- is widely considered to be an important contributor contributing to this increase.

Helminth infection can cause symptoms ranging from mild anaemia through to stomach pain and vomiting, depending on how intense the infection is, but very often people have no symptoms at all. The parasitic worms tend to enter the body through contaminated food or water, mosquito bites or through walking in bare feet on contaminated soil.

A preliminary study carried out at the MRC/UVRI Uganda Research Unit on AIDS in Entebbe, Uganda in 2005 showed a reduced risk of eczema among infants whose mothers had worms and suggested an increased incidence among infants of mothers who received albendazole -- a commonly used drug to treat worm infection -- during pregnancy compared to infants whose mothers received a placebo.

In a follow-up study, researchers carried out a randomised, double-blind trial on 2,507 pregnant women in Uganda, comparing those treated with either albendazole or a second drug, praziquantel, against those administered a placebo, and looking at how this affected their offspring's risk of developing eczema.

Harriet Mpairwe, first author of the new study, says: "Worm infections can adversely affect a person's health, but the evidence also suggests that exposure to infection early in a child's life can have a beneficial effect in terms of modifying its immune system and protecting against allergies. We wanted to examine in a large cohort what effect de-worming women during pregnancy has on their offspring."

The researchers showed for the first time that treatment of pregnant women with albendazole appeared to almost double the risk of eczema in their offspring (an increase by a factor of 1.8) and that treatment with praziquantel more than doubled (an increase by a factor of 2.6) the risk of eczema among infants of mothers infected by the Schistosoma mansoni worm (a parasite which causes the disease schistosomiasis).

The findings support the hypothesis that maternal worms during pregnancy, neonatal life and early breastfeeding, may protect against allergy in infancy and that treatment of these worms during pregnancy increases the risk of allergy.

Professor Alison Elliott from the London School of Hygiene and Tropical Medicine, senior author of the study, says: "Our study suggests that routine de-worming during pregnancy, in settings where most worm infections are mild, may not be beneficial for the children and may actually cause problems with allergy. However, before we recommend changes to treatment policy, we need to do more work to confirm these findings and better understand what is happening.

"The findings certainly support the so-called 'hygiene hypothesis'. What will be important for the eczema story will be to see whether there are long term effects on allergy, especially asthma, at school age. Our next step is to investigate this further."


Story Source:

The above story is based on materials provided by Wellcome Trust. Note: Materials may be edited for content and length.


Journal Reference:

  1. Harriet Mpairwe, Emily L. Webb, Lawrence Muhangi, Juliet Ndibazza, Denise Akishule, Margaret Nampijja, Sophy Ngom-wegi, Josephine Tumusime, Frances M. Jones, Colin Fitzsimmons, David W. Dunne, Moses Muwanga, Laura C. Rodrigues, Alison M. Elliott. Anthelminthic treatment during pregnancy is associated with increased risk of infantile eczema: randomised-controlled trial results. Pediatric Allergy and Immunology, 2011; DOI: 10.1111/j.1399-3038.2010.01122.x

Cite This Page:

Wellcome Trust. "Exposure to worm infection in the womb may protect against eczema, study suggests." ScienceDaily. ScienceDaily, 28 January 2011. <www.sciencedaily.com/releases/2011/01/110128095035.htm>.
Wellcome Trust. (2011, January 28). Exposure to worm infection in the womb may protect against eczema, study suggests. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2011/01/110128095035.htm
Wellcome Trust. "Exposure to worm infection in the womb may protect against eczema, study suggests." ScienceDaily. www.sciencedaily.com/releases/2011/01/110128095035.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins